MedTrace Logo

ATTRACT-52: Primary Care Cardiac Amyloidosis Screening in Ordu, Turkey

NCT07238426 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2026-02-25

No results posted yet for this study

Summary

Cardiac amyloidosis is a progressive infiltrative cardiomyopathy, most commonly related to transthyretin (ATTR) misfolding. Although considered rare, emerging data suggest higher prevalence in specific regions, including the Black Sea area of Turkey. Early recognition improves outcomes. ATTRACT-52 is a prospective, observational, non-interventional screening study in primary care (family medicine centers) across Ordu province. Adults ≥65 years with cardiac or musculoskeletal "red flags" will be screened; those meeting high-suspicion criteria will undergo NT-proBNP/BNP testing at the primary care level to aid risk stratification prior to referral for confirmatory diagnostics.

Conditions

  • Cardiac Amyloidosis
  • Transthyretin Amyloidosis

Sponsors & Collaborators

  • Ordu University, Faculty of Medicine - Department of Cardiology (Academic Collaborator)

    collaborator UNKNOWN

  • Ordu Provincial Health Directorate - Family Medicine Network (Regional Collaborator)

    collaborator UNKNOWN

  • Kotyora Family Medicine Health Management and Education Association

    lead NETWORK

Principal Investigators

  • Seçkin Dereli, MD, Assoc. Prof. · Ordu University Faculty of Medicine, Department of Cardiology (Turkey)

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07238426 on ClinicalTrials.gov